Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication

{ 'indexed': {'date-parts': [[2024, 5, 13]], 'date-time': '2024-05-13T21:14:52Z', 'timestamp': 1715634892014}, 'reference-count': 97, 'publisher': 'Elsevier BV', 'issue': '2', 'license': [ { 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2023, 2, 1]], 'date-time': '2023-02-01T00:00:00Z', 'timestamp': 1675209600000}, 'content-version': 'vor', 'delay-in-days': 365, 'URL': 'http://www.elsevier.com/open-access/userlicense/1.0/'}, { 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-017'}, { 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-037'}, { 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-012'}, { 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-029'}, { 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-004'}], 'content-domain': {'domain': ['elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2022, 2]]}, 'DOI': '10.1016/j.bbadis.2021.166294', 'type': 'journal-article', 'created': { 'date-parts': [[2021, 10, 22]], 'date-time': '2021-10-22T01:41:47Z', 'timestamp': 1634866907000}, 'page': '166294', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 30, 'title': 'Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against ' 'SARS-CoV-2 replication', 'prefix': '10.1016', 'volume': '1868', 'author': [ {'given': 'Zheng Yao', 'family': 'Low', 'sequence': 'first', 'affiliation': []}, {'given': 'Ashley Jia Wen', 'family': 'Yip', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sunil K.', 'family': 'Lal', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.bbadis.2021.166294_bb0010', 'doi-asserted-by': 'crossref', 'first-page': '450', 'DOI': '10.1038/s41591-020-0820-9', 'article-title': 'The proximal origin of SARS-CoV-2', 'volume': '26', 'author': 'Andersen', 'year': '2020', 'journal-title': 'Nat. Med.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0015', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fphar.2020.00836', 'article-title': 'Molecular insights into SARS COV-2 interaction with cardiovascular ' 'disease: role of RAAS and MAPK signaling', 'volume': '11', 'author': 'Wehbe', 'year': '2020', 'journal-title': 'Front. Pharmacol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0020', 'doi-asserted-by': 'crossref', 'first-page': '1058', 'DOI': '10.3390/v12091058', 'article-title': 'Drug repositioning: new approaches and future prospects for ' 'life-debilitating diseases and the COVID-19 pandemic outbreak', 'volume': '12', 'author': 'Low', 'year': '2020', 'journal-title': 'Viruses'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0025', 'first-page': '202', 'article-title': 'COVID-19: a review on the novel coronavirus disease evolution, ' 'transmission, detectionControl and Prevention', 'volume': '13', 'author': 'Sharma', 'year': '2021'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0030', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.jmgm.2020.107762', 'article-title': 'Prediction of potential inhibitors of the dimeric SARS-CoV2 main ' 'proteinase through the MM/GBSA approach', 'volume': '101', 'author': 'Bello', 'year': '2020', 'journal-title': 'J. Mol. Graph. Model.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0035', 'doi-asserted-by': 'crossref', 'DOI': '10.1007/s00894-020-04600-4', 'article-title': 'Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 ' 'main protease through MM/GBSA', 'volume': '26', 'author': 'Bello', 'year': '2020', 'journal-title': 'J. Mol. Model.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0040', 'doi-asserted-by': 'crossref', 'first-page': '454', 'DOI': '10.3390/ph14050454', 'article-title': 'Tenofovir, another inexpensive, well-known and widely available old ' 'drug repurposed for SARS-COV-2 infection', 'volume': '14', 'author': 'Zanella', 'year': '2021', 'journal-title': 'Pharmaceuticals'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0045', 'doi-asserted-by': 'crossref', 'DOI': '10.1128/AAC.00819-20', 'article-title': 'Identification of antiviral drug candidates against SARS-CoV-2 from ' 'FDA-approved drugs', 'volume': '64', 'author': 'Jeon', 'year': '2020', 'journal-title': 'Antimicrob. Agents Chemother.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0050', 'doi-asserted-by': 'crossref', 'first-page': '463', 'DOI': '10.1016/j.pt.2017.02.004', 'article-title': 'Ivermectin – old drug, new Tricks?', 'volume': '33', 'author': 'Laing', 'year': '2017', 'journal-title': 'Trends Parasitol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0055', 'doi-asserted-by': 'crossref', 'first-page': '91', 'DOI': '10.1016/j.ijantimicag.2007.08.023', 'article-title': 'Ivermectin: 25 years and still going strong', 'volume': '31', 'author': 'Õmura', 'year': '2008', 'journal-title': 'Int. J. Antimicrob. Agents'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0060', 'doi-asserted-by': 'crossref', 'first-page': '823', 'DOI': '10.1126/science.6308762', 'article-title': 'Ivermectin: a potent new antiparasitic agent', 'volume': '221', 'author': 'Campbell', 'year': '1983', 'journal-title': 'Science'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0065', 'doi-asserted-by': 'crossref', 'first-page': '984', 'DOI': '10.1038/nrmicro1048', 'article-title': 'The life and times of ivermectin — a success story', 'volume': '2', 'author': 'Õmura', 'year': '2004', 'journal-title': 'Nat. Rev. Microbiol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0070', 'doi-asserted-by': 'crossref', 'first-page': '134', 'DOI': '10.1016/j.ijantimicag.2019.05.003', 'article-title': 'Ivermectin: from theory to clinical application', 'volume': '54', 'author': 'Ashour', 'year': '2019', 'journal-title': 'Int. J. Antimicrob. Agents'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0075', 'doi-asserted-by': 'crossref', 'first-page': 'A26', 'DOI': '10.1111/j.1365-3156.2004.01211.x', 'article-title': 'Review: the delivery of ivermectin (MectizanR)', 'volume': '9', 'author': 'Burnham', 'year': '2004', 'journal-title': 'Trop. Med. Int. Health'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0080', 'doi-asserted-by': 'crossref', 'first-page': '381', 'DOI': '10.3390/antibiotics10040381', 'article-title': 'Repurposing avermectins and milbemycins against mycobacteroides ' 'abscessus and other nontuberculous mycobacteria', 'volume': '10', 'author': 'Muñoz-Muñoz', 'year': '2021', 'journal-title': 'Antibiotics'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0085', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.phrs.2020.105207', 'article-title': 'Ivermectin, a potential anticancer drug derived from an antiparasitic ' 'drug', 'volume': '163', 'author': 'Tang', 'year': '2021', 'journal-title': 'Pharmacol. Res.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0090', 'doi-asserted-by': 'crossref', 'first-page': '2553', 'DOI': '10.1093/brain/awv167', 'article-title': 'DEAD-box RNA helicase DDX23 modulates glioma malignancy via elevating ' 'miR-21 biogenesis', 'volume': '138', 'author': 'Yin', 'year': '2015', 'journal-title': 'Brain'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0095', 'doi-asserted-by': 'crossref', 'DOI': '10.1038/srep17288', 'article-title': 'Selective targeting of nuclear receptor FXR by avermectin analogues ' 'with therapeutic effects on nonalcoholic fatty liver disease', 'volume': '5', 'author': 'Jin', 'year': '2015', 'journal-title': 'Sci. Rep.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0100', 'doi-asserted-by': 'crossref', 'first-page': '1884', 'DOI': '10.1093/jac/dks147', 'article-title': 'Ivermectin is a potent inhibitor of flavivirus replication specifically ' 'targeting NS3 helicase activity: new prospects for an old drug', 'volume': '67', 'author': 'Mastrangelo', 'year': '2012', 'journal-title': 'J. Antimicrob. Chemother.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0105', 'doi-asserted-by': 'crossref', 'first-page': '851', 'DOI': '10.1042/BJ20120150', 'article-title': 'Ivermectin is a specific inhibitor of importin α/β-mediated nuclear ' 'import able to inhibit replication of HIV-1 and dengue virus', 'volume': '443', 'author': 'Wagstaff', 'year': '2012', 'journal-title': 'Biochem. J.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0110', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.antiviral.2020.104787', 'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 ' 'in vitro', 'volume': '178', 'author': 'Caly', 'year': '2020', 'journal-title': 'Antivir. Res.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0115', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fimmu.2021.663586', 'article-title': 'Repurposing ivermectin for COVID-19: molecular aspects and therapeutic ' 'possibilities', 'volume': '12', 'author': 'Wehbe', 'year': '2021', 'journal-title': 'Front. Immunol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0120', 'doi-asserted-by': 'crossref', 'first-page': '174', 'DOI': '10.1080/00480169.1981.34836', 'article-title': 'An introduction to the avermectins', 'volume': '29', 'author': 'Campbell', 'year': '1981', 'journal-title': 'N. Z. Vet. J.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0125', 'doi-asserted-by': 'crossref', 'first-page': '736', 'DOI': '10.1007/s43440-020-00195-y', 'article-title': 'Ivermectin as a potential drug for treatment of COVID-19: an in-sync ' 'review with clinical and computational attributes', 'volume': '73', 'author': 'Kaur', 'year': '2021', 'journal-title': 'Pharmacol. Rep.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0130', 'doi-asserted-by': 'crossref', 'first-page': '2100', 'DOI': '10.3390/cells9092100', 'article-title': 'Ivermectin as a broad-Spectrum host-directed antiviral: the real deal?', 'volume': '9', 'author': 'Jans', 'year': '2020', 'journal-title': 'Cells'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0135', 'doi-asserted-by': 'crossref', 'first-page': '1156', 'DOI': '10.4269/ajtmh.20-0271', 'article-title': 'Ivermectin and COVID-19: keeping rigor in times of urgency', 'volume': '102', 'author': 'Chaccour', 'year': '2020', 'journal-title': 'Am. J. Trop. Med. Hyg.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0140', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fphar.2020.01196', 'article-title': 'COVID-19 therapeutic options under investigation', 'volume': '11', 'author': 'Kaddoura', 'year': '2020', 'journal-title': 'Front. Pharmacol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0145', 'doi-asserted-by': 'crossref', 'first-page': '9812', 'DOI': '10.1128/JVI.01012-07', 'article-title': 'Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 ' 'function by sequestering nuclear import factors on the rough ' 'endoplasmic reticulum/golgimembrane', 'volume': '81', 'author': 'Frieman', 'year': '2007', 'journal-title': 'J. Virol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0150', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fmicb.2015.00553', 'article-title': 'Nucleocytoplasmic transport of nucleocapsid proteins of enveloped RNA ' 'viruses', 'volume': '6', 'author': 'Wulan', 'year': '2015', 'journal-title': 'Front. Microbiol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0155', 'doi-asserted-by': 'crossref', 'first-page': '259', 'DOI': '10.1016/j.chom.2016.07.004', 'article-title': 'A screen of FDA-approved drugs for inhibitors of zika virus infection', 'volume': '20', 'author': 'Barrows', 'year': '2016', 'journal-title': 'Cell Host Microbe'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0160', 'doi-asserted-by': 'crossref', 'first-page': '1552', 'DOI': '10.1056/NEJMra1602113', 'article-title': 'Zika virus', 'volume': '374', 'author': 'Petersen', 'year': '2016', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0170', 'doi-asserted-by': 'crossref', 'first-page': '124', 'DOI': '10.1016/j.virol.2019.10.010', 'article-title': 'Zika virus NS5 nuclear accumulation is protective of protein ' 'degradation and is required for viral RNA replication', 'volume': '541', 'author': 'Ji', 'year': '2020', 'journal-title': 'Virology'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0175', 'doi-asserted-by': 'crossref', 'first-page': '635', 'DOI': '10.1128/CMR.00045-12', 'article-title': 'West Nile virus: biology, transmission, and human infection', 'volume': '25', 'author': 'Colpitts', 'year': '2012', 'journal-title': 'Clin. Microbiol. Rev.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0180', 'doi-asserted-by': 'crossref', 'first-page': '1884', 'DOI': '10.1093/jac/dks147', 'article-title': 'Ivermectin is a potent inhibitor of flavivirus replication specifically ' 'targeting NS3 helicase activity: new prospects for an old drug', 'volume': '67', 'author': 'Mastrangelo', 'year': '2012', 'journal-title': 'J. Antimicrob. Chemother.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0185', 'doi-asserted-by': 'crossref', 'first-page': '402', 'DOI': '10.1016/j.cell.2009.01.029', 'article-title': 'The influenza virus enigma', 'volume': '136', 'author': 'Salomon', 'year': '2009', 'journal-title': 'Cell'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0190', 'article-title': 'Influenza a viruses escape from MxA restriction at the expense of ' 'efficient nuclear vRNP import', 'volume': '6', 'author': 'Götz', 'year': '2016', 'journal-title': 'Sci. Rep.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0195', 'doi-asserted-by': 'crossref', 'first-page': '13053', 'DOI': '10.1128/JVI.02220-13', 'article-title': 'The human interferon-induced MxA protein inhibits early stages of ' 'influenza a virus infection by retaining the incoming viral genome in ' 'the cytoplasm', 'volume': '87', 'author': 'Xiao', 'year': '2013', 'journal-title': 'J. Virol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0200', 'doi-asserted-by': 'crossref', 'first-page': '8133', 'DOI': '10.1128/JVI.00712-11', 'article-title': 'The viral nucleoprotein determines mx sensitivity of influenza a ' 'viruses', 'volume': '85', 'author': 'Zimmermann', 'year': '2011', 'journal-title': 'J. Virol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0205', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fimmu.2018.01547', 'article-title': 'Advancements in host-based interventions for influenza treatment', 'volume': '9', 'author': 'Yip', 'year': '2018', 'journal-title': 'Front. Immunol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0210', 'doi-asserted-by': 'crossref', 'first-page': '217', 'DOI': '10.1021/cb600131q', 'article-title': 'Following the path of the virus: the exploitation of host DNA repair ' 'mechanisms by retroviruses', 'volume': '1', 'author': 'Smith', 'year': '2006', 'journal-title': 'ACS Chem. Biol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0215', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.antiviral.2020.104760', 'article-title': 'The broad spectrum antiviral ivermectin targets the host nuclear ' 'transport importin α/β1 heterodimer', 'volume': '177', 'author': 'Yang', 'year': '2020', 'journal-title': 'Antivir. Res.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0220', 'doi-asserted-by': 'crossref', 'first-page': '270', 'DOI': '10.1038/s41586-020-2012-7', 'article-title': 'A pneumonia outbreak associated with a new coronavirus of probable bat ' 'origin', 'volume': '579', 'author': 'Zhou', 'year': '2020', 'journal-title': 'Nature'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0225', 'doi-asserted-by': 'crossref', 'first-page': '91', 'DOI': '10.1016/j.jare.2020.03.005', 'article-title': 'COVID-19 infection: emergence, transmission, and characteristics of ' 'human coronaviruses', 'volume': '24', 'author': 'Shereen', 'year': '2020', 'journal-title': 'J. Adv. Res.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0230', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.bbadis.2020.165878', 'article-title': 'Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and ' 'therapies: structural genomics approach', 'volume': '1866', 'author': 'Naqvi', 'year': '2020', 'journal-title': 'Biochim. Biophys. Acta (BBA) - Mol. Basis Dis.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0235', 'first-page': '1', 'article-title': 'Coronaviruses: an overview of their replication and pathogenesis', 'author': 'Fehr', 'year': '2015', 'journal-title': 'Coronaviruses'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0240', 'doi-asserted-by': 'crossref', 'first-page': '7918', 'DOI': '10.1128/JVI.00645-06', 'article-title': 'Supramolecular architecture of severe acute respiratory syndrome ' 'coronavirus revealed by electron cryomicroscopy', 'volume': '80', 'author': 'Neuman', 'year': '2006', 'journal-title': 'J. Virol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0245', 'first-page': '1', 'article-title': 'Binding mechanism and structural insights into the identified protein ' 'target of COVID-19 and importin-α with in-vitro effective drug ' 'ivermectin', 'author': 'Sen Gupta', 'year': '2020', 'journal-title': 'J. Biomol. Struct. Dyn.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0250', 'doi-asserted-by': 'crossref', 'first-page': '9812', 'DOI': '10.1128/JVI.01012-07', 'article-title': 'Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 ' 'function by sequestering nuclear import factors on the rough ' 'endoplasmic Reticulum/Golgi membrane', 'volume': '81', 'author': 'Frieman', 'year': '2007', 'journal-title': 'J. Virol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0255', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ejmech.2021.113201', 'article-title': 'RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape ' 'and repurposing for the COVID-19 pandemic', 'volume': '213', 'author': 'Tian', 'year': '2021', 'journal-title': 'Eur. J. Med. Chem.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0260', 'first-page': '1', 'article-title': 'The binding mechanism of ivermectin and levosalbutamol with spike ' 'protein of SARS-CoV-2', 'author': 'Saha', 'year': '2021', 'journal-title': 'Struct. Chem.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0265', 'doi-asserted-by': 'crossref', 'DOI': '10.1038/s42003-020-01577-x', 'article-title': 'Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as ' 'potential anti-SARS-CoV-2 agents', 'volume': '4', 'author': 'Mody', 'year': '2021', 'journal-title': 'Commun. Biol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0270', 'doi-asserted-by': 'crossref', 'first-page': '50', 'DOI': '10.1016/j.ceb.2019.01.001', 'article-title': 'Inhibitors of nuclear transport', 'volume': '58', 'author': 'Jans', 'year': '2019', 'journal-title': 'Curr. Opin. Cell Biol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0275', 'doi-asserted-by': 'crossref', 'first-page': '202', 'DOI': '10.1016/j.antiviral.2012.06.008', 'article-title': 'Nuclear trafficking of proteins from RNA viruses: potential target for ' 'antivirals?', 'volume': '95', 'author': 'Caly', 'year': '2012', 'journal-title': 'Antivir. Res.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0280', 'doi-asserted-by': 'crossref', 'first-page': '281', 'DOI': '10.3390/cells8030281', 'article-title': 'Novel flavivirus antiviral that targets the host nuclear transport ' 'importin α/β1 heterodimer', 'volume': '8', 'author': 'Yang', 'year': '2019', 'journal-title': 'Cells'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0285', 'unstructured': 'Waheed Shouman . Prophylactic Ivermectin in COVID-19 Contacts - Study ' 'Results - ClinicalTrials.gov ' 'https://clinicaltrials.gov/ct2/show/results/NCT04422561 (Accessed Jun ' '10, 2021).'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0290', 'article-title': 'Ivermectin and outcomes from Covid-19 pneumonia: a systematic review ' 'and meta-analysis of randomized clinical trial studies', 'author': 'Hariyanto', 'year': '2021', 'journal-title': 'Rev. Med. Virol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0295', 'series-title': 'Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a ' 'therapeutic drug against SARS-CoV2: Evidence from in silico studies', 'author': 'Swargiary', 'year': '2020'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0300', 'doi-asserted-by': 'crossref', 'first-page': '3209', 'DOI': '10.1038/s41418-020-00633-7', 'article-title': 'An aberrant STAT pathway is central to COVID-19', 'volume': '27', 'author': 'Matsuyama', 'year': '2020', 'journal-title': 'Cell Death Differ.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0305', 'doi-asserted-by': 'crossref', 'first-page': '870', 'DOI': '10.1016/j.chom.2020.05.008', 'article-title': 'Type I and type III interferons – induction, signaling, evasion, and ' 'application to combat COVID-19', 'volume': '27', 'author': 'Park', 'year': '2020', 'journal-title': 'Cell Host Microbe'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0310', 'doi-asserted-by': 'crossref', 'first-page': '10262', 'DOI': '10.1074/jbc.M116.745729', 'article-title': 'Enterovirus 71 suppresses interferon responses by blocking Janus kinase ' '(JAK)/signal transducer and activator of transcription (STAT) signaling ' 'through inducing karyopherin-α1 degradation', 'volume': '292', 'author': 'Wang', 'year': '2017', 'journal-title': 'J. Biol. Chem.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0315', 'doi-asserted-by': 'crossref', 'first-page': '4870', 'DOI': '10.3390/ijms20194870', 'article-title': 'STAT3 regulates the type I IFN-mediated antiviral response by ' 'interfering with the nuclear entry of STAT1', 'volume': '20', 'author': 'Wang', 'year': '2019', 'journal-title': 'Int. J. Mol. Sci.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0320', 'doi-asserted-by': 'crossref', 'first-page': '395', 'DOI': '10.1165/rcmb.2012-0100TR', 'article-title': 'Human epidermal growth factor receptor signaling in acute lung injury', 'volume': '47', 'author': 'Finigan', 'year': '2012', 'journal-title': 'Am. J. Respir. Cell Mol. Biol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0325', 'doi-asserted-by': 'crossref', 'first-page': '503', 'DOI': '10.1016/j.bbrc.2016.06.065', 'article-title': 'Plasminogen activator inhibitor-1 stimulates macrophage activation ' 'through toll-like Receptor-4', 'volume': '477', 'author': 'Gupta', 'year': '2016', 'journal-title': 'Biochem. Biophys. Res. Commun.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0330', 'doi-asserted-by': 'crossref', 'first-page': '499', 'DOI': '10.1165/rcmb.2008-0003ED', 'article-title': 'What the lung has taught us about latent TGF-β activation', 'volume': '39', 'author': 'Aluwihare', 'year': '2008', 'journal-title': 'Am. J. Respir. Cell Mol. Biol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0335', 'doi-asserted-by': 'crossref', 'first-page': '855', 'DOI': '10.4049/jimmunol.1402513', 'article-title': 'The acute respiratory distress syndrome: from mechanism to translation', 'volume': '194', 'author': 'Han', 'year': '2015', 'journal-title': 'J. Immunol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0340', 'doi-asserted-by': 'crossref', 'first-page': '4457', 'DOI': '10.1158/0008-5472.CAN-15-2887', 'article-title': 'Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt Axis ' 'in breast cancer', 'volume': '76', 'author': 'Dou', 'year': '2016', 'journal-title': 'Cancer Res.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0345', 'doi-asserted-by': 'crossref', 'first-page': '1737', 'DOI': '10.3390/ijms22041737', 'article-title': 'Understanding viral infection mechanisms and patient symptoms for the ' 'development of COVID-19 therapeutics', 'volume': '22', 'author': 'Choi', 'year': '2021', 'journal-title': 'Int. J. Mol. Sci.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0350', 'doi-asserted-by': 'crossref', 'first-page': '621', 'DOI': '10.1038/s41423-020-0458-z', 'article-title': 'Key residues of the receptor binding motif in the spike protein of ' 'SARS-CoV-2 that interact with ACE2 and neutralizing antibodies', 'volume': '17', 'author': 'Yi', 'year': '2020', 'journal-title': 'Cell. Mol. Immunol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0355', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.gene.2020.145325', 'article-title': 'The potential involvement of JAK-STAT signalling pathway in the ' 'COVID-19 infection assisted by ACE2', 'volume': '768', 'author': 'Luo', 'year': '2021', 'journal-title': 'Gene'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0360', 'series-title': 'Activation of the SARS-CoV-2 receptorAce2by cytokines through pan ' 'JAK-STAT enhancers', 'author': 'Hennighausen', 'year': '2020'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0365', 'doi-asserted-by': 'crossref', 'first-page': '277', 'DOI': '10.2217/fvl-2020-0342', 'article-title': 'Exploring the binding efficacy of ivermectin against the key proteins ' 'of SARS-CoV-2 pathogenesis: an in-silico approach', 'volume': '16', 'author': 'Choudhury', 'year': '2021', 'journal-title': 'Futur. Virol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0370', 'doi-asserted-by': 'crossref', 'first-page': '3023', 'DOI': '10.21873/invivo.12134', 'article-title': 'Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain ' 'attached to ACE2', 'volume': '34', 'author': 'Lehrer', 'year': '2020', 'journal-title': 'In Vivo'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0375', 'first-page': '1', 'article-title': 'Elucidation of the inhibitory activity of ivermectin with host nuclear ' 'importin α and several SARS-CoV-2 targets', 'author': 'Bello', 'year': '2021', 'journal-title': 'J. Biomol. Struct. Dyn.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0380', 'doi-asserted-by': 'crossref', 'DOI': '10.1038/s41598-021-88630-9', 'article-title': 'The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected ' 'by small molecule inhibitors', 'volume': '11', 'author': 'Silvestrini', 'year': '2021', 'journal-title': 'Sci. Rep.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0385', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.jmgm.2020.107762', 'article-title': 'Prediction of potential inhibitors of the dimeric SARS-CoV2 main ' 'proteinase through the MM/GBSA approach', 'volume': '101', 'author': 'Bello', 'year': '2020', 'journal-title': 'J. Mol. Graph. Model.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0390', 'doi-asserted-by': 'crossref', 'first-page': '409', 'DOI': '10.1126/science.abb3405', 'article-title': 'Crystal structure of SARS-CoV-2 main protease provides a basis for ' 'design of improved α-ketoamide inhibitors', 'volume': '368', 'author': 'Zhang', 'year': '2020', 'journal-title': 'Science'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0395', 'doi-asserted-by': 'crossref', 'first-page': '289', 'DOI': '10.1038/s41586-020-2223-y', 'article-title': 'Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors', 'volume': '582', 'author': 'Jin', 'year': '2020', 'journal-title': 'Nature'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0400', 'doi-asserted-by': 'crossref', 'first-page': '483', 'DOI': '10.1107/S2053230X20011814', 'article-title': 'Room-temperature neutron and X-ray data collection of 3CL mprofrom ' 'SARS-CoV-2', 'volume': '76', 'author': 'Kneller', 'year': '2020', 'journal-title': 'Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0405', 'article-title': 'Design of wide-spectrum inhibitors targeting coronavirus main proteases', 'volume': '3', 'author': 'Yang', 'year': '2005', 'journal-title': 'PLoS Biol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0410', 'doi-asserted-by': 'crossref', 'first-page': '1331', 'DOI': '10.1126/science.abb4489', 'article-title': 'Structure-based design of antiviral drug candidates targeting the ' 'SARS-CoV-2 main protease', 'volume': '368', 'author': 'Dai', 'year': '2020', 'journal-title': 'Science'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0415', 'doi-asserted-by': 'crossref', 'first-page': '861', 'DOI': '10.1016/j.jtbi.2008.07.030', 'article-title': 'Molecular dynamic simulations analysis of ritronavir and lopinavir as ' 'SARS-CoV 3CLpro inhibitors', 'volume': '254', 'author': 'Nukoolkarn', 'year': '2008', 'journal-title': 'J. Theor. Biol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0420', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.antiviral.2020.104786', 'article-title': 'Remdesivir, lopinavir, emetine, and homoharringtonine inhibit ' 'SARS-CoV-2 replication in vitro', 'volume': '178', 'author': 'Choy', 'year': '2020', 'journal-title': 'Antivir. Res.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0425', 'doi-asserted-by': 'crossref', 'first-page': '1787', 'DOI': '10.1056/NEJMoa2001282', 'article-title': 'A trial of lopinavir-ritonavir in adults hospitalized with severe ' 'Covid-19', 'volume': '382', 'author': 'Cao', 'year': '2020', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0430', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fmolb.2020.616341', 'article-title': 'Recent Progress in the drug development targeting SARS-CoV-2 Main ' 'protease as treatment for COVID-19', 'volume': '7', 'author': 'Cui', 'year': '2020', 'journal-title': 'Front. Mol. Biosci.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0435', 'doi-asserted-by': 'crossref', 'first-page': '1763', 'DOI': '10.1126/science.1085658', 'article-title': 'Coronavirus main proteinase (3CLpro) structure: basis for design of ' 'anti-SARS drugs', 'volume': '300', 'author': 'Anand', 'year': '2003', 'journal-title': 'Science'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0440', 'doi-asserted-by': 'crossref', 'first-page': '861', 'DOI': '10.1016/j.jtbi.2008.07.030', 'article-title': 'Molecular dynamic simulations analysis of ritronavir and lopinavir as ' 'SARS-CoV 3CLpro inhibitors', 'volume': '254', 'author': 'Nukoolkarn', 'year': '2008', 'journal-title': 'J. Theor. Biol.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0445', 'doi-asserted-by': 'crossref', 'first-page': '349', 'DOI': '10.1080/1061186X.2020.1853736', 'article-title': 'Potential inhibitors of SARS-CoV-2: recent advances', 'volume': '29', 'author': 'Jamalipour Soufi', 'year': '2020', 'journal-title': 'J. Drug Target.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0450', 'doi-asserted-by': 'crossref', 'first-page': '989', 'DOI': '10.3390/v13060989', 'article-title': 'Effects of a single dose of ivermectin on viral and clinical outcomes ' 'in asymptomatic SARS-CoV-2 infected subjects: a pilot clinical trial in ' 'Lebanon', 'volume': '13', 'author': 'Samaha', 'year': '2021', 'journal-title': 'Viruses'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0455', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/S1473-3099(20)30883-5', 'article-title': 'Ct values and infectivity of SARS-CoV-2 on surfaces', 'volume': '21', 'author': 'Kampf', 'year': '2021', 'journal-title': 'Lancet Infect. Dis.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0460', 'doi-asserted-by': 'crossref', 'first-page': 'e299', 'DOI': '10.1097/MJT.0000000000001377', 'article-title': 'Review of the emerging evidence demonstrating the efficacy of ' 'ivermectin in the prophylaxis and treatment of COVID-19', 'volume': '28', 'author': 'Kory', 'year': '2021', 'journal-title': 'Am. J. Ther.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0465', 'series-title': 'Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of ' 'COVID-19 Pandemic', 'author': 'Elgazzar', 'year': '2020'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0470', 'doi-asserted-by': 'crossref', 'DOI': '10.31546/2633-8653.1007', 'article-title': 'Study of the efficacy and safety of topical ivermectin + ' 'iota-carrageenan in the prophylaxis against COVID-19 in health ' 'personnel', 'volume': '2', 'author': 'Héctor', 'year': '2020', 'journal-title': 'J. Biomed. Res. Clin. Investig.'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0475', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pone.0242184', 'article-title': 'Lack of efficacy of standard doses of ivermectin in severe COVID-19 ' 'patients', 'volume': '15', 'author': 'Camprubí', 'year': '2020', 'journal-title': 'PLOS ONE'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0480', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.eclinm.2021.100959', 'article-title': 'Antiviral effect of high-dose ivermectin in adults with COVID-19: a ' 'proof-of-concept randomized trial', 'volume': '37', 'author': 'Krolewiecki', 'year': '2021', 'journal-title': 'EClinicalMedicine'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0485', 'doi-asserted-by': 'crossref', 'first-page': '1426', 'DOI': '10.1001/jama.2021.3071', 'article-title': 'Effect of ivermectin on time to resolution of symptoms among adults ' 'with mild COVID-19', 'volume': '325', 'author': 'López-Medina', 'year': '2021', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0490', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.eclinm.2021.100744', 'article-title': 'Is ivermectin ready to be part of a public health policy for COVID-19 ' 'prophylaxis?', 'volume': '32', 'author': 'Ramírez', 'year': '2021', 'journal-title': 'EClinicalMedicine'}, { 'key': '10.1016/j.bbadis.2021.166294_bb0495', 'doi-asserted-by': 'crossref', 'first-page': '762', 'DOI': '10.1002/cpt.1889', 'article-title': 'The approved dose of ivermectin alone is not the ideal dose for the ' 'treatment of COVID-19', 'volume': '108', 'author': 'Schmith', 'year': '2020', 'journal-title': 'Clin. Pharmacol. Ther.'}], 'container-title': 'Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0925443921002271?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0925443921002271?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2023, 3, 6]], 'date-time': '2023-03-06T15:26:35Z', 'timestamp': 1678116395000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0925443921002271'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 2]]}, 'references-count': 97, 'journal-issue': {'issue': '2', 'published-print': {'date-parts': [[2022, 2]]}}, 'alternative-id': ['S0925443921002271'], 'URL': 'http://dx.doi.org/10.1016/j.bbadis.2021.166294', 'relation': {}, 'ISSN': ['0925-4439'], 'subject': [], 'container-title-short': 'Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease', 'published': {'date-parts': [[2022, 2]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action ' 'against SARS-CoV-2 replication', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.bbadis.2021.166294', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, {'value': '© 2021 Elsevier B.V.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '166294'}